BioNTech, DualityBio steer ADC into PhIII, with aim to compete in HER2-low subgroup with Enhertu
BioNTech is stepping on AstraZeneca and Daiichi Sankyo’s turf with the launch of a Phase III trial for its antibody-drug conjugate aiming at a subset …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.